ArticlePakistan journal of medical sciences2025
Establishing a mathematical standard model for calculating the volume of peripheral arteriovenous synchronous blood exchange transfusion in neonates with severe hyperbilirubinemia.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study the optimal blood exchange transfusion (BET) capacity in neonates with severe hyperbilirubinemia and establish a mathematical standard model for calculating the volume of BET. Methods: The clinical data of 30 neonates with severe hyperbilirubinemia who received BET in the NICU of Sixth Affiliated Hospital of Nantong University between January, 2016 to December, 2022 were analyzed retrospectively. All neonates received single-volume exchange transfusion (SVET). Serum bilirubin levels were measured every 15 minutes, and serum calcium, blood glucose, hemoglobin, and platelet levels were monitored every 30 minutes of the procedure. The observation decline curve of bilirubin was plotted, and a standard mathematical model for the arteriovenous synchronous exchange transfusion was established. The standard control curve was then calculated, and the two curves were analyzed and compared. The incidence of adverse events was compared between the first and the second half of BET. Results: There was a statistically significant difference in hemoglobin levels and platelet counts between different points of the procedure (0, 30, 60, 90, and 120 minutes; F = 12.710, 68.620; P < 0.001). During exchange transfusion, there was a significant decline in bilirubin levels every 30 minutes (F = 5273.00, P < 0.05). The clearance of total serum bilirubin (TSB) in the first half of the BET was higher, and the incidence rate of major adverse events was significantly lower than in the second half (P < 0.05). Conclusions: SVET can effectively reduce total serum bilirubin levels in neonates with severe hyperbilirubinemia. Clinicians may use SVET for treating the condition in combination with phototherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.